Kouichi Ohta, Katsuyuki Obara. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Antiparkinson Agents/adverse effectsAntiparkinson Agents/therapeutic useBrain Stem Infarctions/diagnosisBrain Stem Infarctions/physiopathologyCarbidopa/adverse effectsCarbidopa/therapeutic useCerebral Infarction/diagnosisCerebral Infarction/physiopathologyDiagnosis, DifferentialDominance, Cerebral/physiologyDrug Therapy, CombinationFollow-Up StudiesHumansLevodopa/adverse effectsLevodopa/therapeutic useMagnetic Resonance ImagingMaleMiddle AgedNeurologic ExaminationParkinsonian Disorders/diagnosisParkinsonian Disorders/drug therapyParkinsonian Disorders/physiopathologySubstantia Nigra/blood supplySubstantia Nigra/physiopathologyTomography, Emission-Computed, Single-Photon
Substances: See more » Antiparkinson AgentsLevodopaCarbidopa
Year: 2006 PMID: 16229001 DOI: 10.1002/mds.20747
Source DB: PubMed Journal: Mov Disord ISSN: 0885-3185 Impact factor: 10.338